ShuJie Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
ShuJie Chen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- CanMing Chen
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai 200032, PR China
1 shared publication - GuangYu Liu
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai 200032, PR China
1 shared publication - JiaYi Wu
Department of Surgery, RuiJin Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, PR China
1 shared publication - JingSong Lu
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai 200032, PR China
1 shared publication - Jiong Wu
Department of Breast Surgery, Cancer Hospital, Fudan University, Shanghai 200032, PR China
1 shared publication - Kunwei Shen
Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
1 shared publication
Latest Publications
- Open Access
- 21 October 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 375
Retrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy (NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at identification of predictive markers for the long-term outcome in noninflammatory locally advanced breast cancer (NLABC).
- 21 October 2009
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 375
Open AccessRetrospective analysis of 119 Chinese noninflammatory locally advanced breast cancer cases treated with intravenous combination of vinorelbine and epirubicin as a neoadjuvant chemotherapy: a median follow-up of 63.4 months
This study is a retrospective evaluation of the efficacy of neoadjuvant chemotherapy (NC) with a vinorelbine (V) and epirubicin (E) intravenous combination regimen and is aimed at identification of predictive markers for the long-term outcome in noninflammatory locally advanced breast cancer (NLABC).